Bengi Ozturk

Dr. Bengi Ozturk

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2024 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
BOBengi Ozturk
Bengi Ozturk
KCKoray Ceyhan
Koray Ceyhan
MBMehmet Bektaş
Mehmet Bektaş
Background/Aims: Radiological imaging advancements have led to a rise in pancreatic cyst diagnoses. Apart from imaging modalities, endoscopic ultrasonography (EUS) is an important method in the diagnosis of pancreatic cysts. The aim of this study is to determine the clinical, laboratory, biochemical, radiological, and endosonographic features of pancreatic cysts and to assess the effectiveness of EUS and computed tomography (CT) in differentiating between neoplastic and nonneoplastic cysts. Materials and Methods: Patients with pancreatic cysts diagnosed by CT, who underwent EUS at the EUS Laboratory of Ankara University Faculty of Medicine, Gastroenterology Department, between 2010 and 2015, were retrospectively evaluated. Size, location, number, and morphological features were compared. Samples for cytology and biochemical tests were obtained through EUS-guided fine needle aspiration (EUS-FNA). Results: The study group included 212 patients. Among them, 125 (59%) patients underwent EUS-FNA. Of these, 63 (52%) were neoplastic, 29 (24%) were nonneoplastic, and 29 (24%) lacked subgroup analysis. The sensitivity of CT in differentiating between neoplastic and nonneoplastic cysts was 82.1% [CI, 68.2%-91.9%], with a specificity of 61.1% (CI, 38.2%-81%) and diagnostic accuracy of 75.4%. Regarding EUS, the sensitivity was 96.7% (CI, 90.2%-99.4%), with a specificity of 45.8% (CI, 27.1%-65.4%) and diagnostic accuracy of 82.3%. Conclusion: Endoscopic ultrasonography demonstrated enhanced sensitivity compared with CT in differentiating neoplastic from nonneoplastic pancreatic cysts. Although no statistical significance was found, this result can be considered clinically remarkable. In addition, EUS displayed distinct advantages in visualizing specific morphological features, emphasizing its potential as a valuable diagnostic tool in assessing pancreatic cystic neoplasms. Cite this article as: Öztürk B, Ceyhan K, Bektaş M. The effectiveness of endoscopic ultrasonography and computed tomography in the differentiation of pancreatic cystic neoplasms: A single-center experience. Turk J Gastroenterol. 2024;35(12):945-953.

19 December 2023 in Cureus
Verified
Journal Article
Open access
PDF file
BOBengi Ozturk
Bengi Ozturk
Aim The aim of this study is to define genomic variations between fibrolamellar hepatocellular carcinoma (FL-HCC) and conventional hepatocellular carcinoma (HCC) Methods This study used the American Association for Cancer Research (AACR) Project GENIE data as a foundational element. Specifically, information about both fibrolamellar and conventional hepatocellular carcinoma was retrieved from this database. Results A total of 719 patients diagnosed with HCC and 52 individuals presenting with FL-HCC underwent thorough analysis. Notably, distinct variances in gene alterations were observed between the two cohorts. Predominantly, the HCC group exhibited frequent occurrences of mutations within the TP53 and CTNNB1 genes. Conversely, DNAJB1 fusion was uniquely identified in FL-HCC cases. Conclusion This study significantly broadens our understanding of the genetic makeup associated with FL-HCC and HCC. It is particularly notable because it reveals clear disparities in gene modifications between FL-HCC and HCC. Further investigation is essential to unravel the functional consequences of these genetic variances. This exploration will aid in the development of targeted therapeutic approaches to enhance the prognosis of patients diagnosed with diverse subtypes of HCC.

25 April 2024 in Akademik Gastroenteroloji Dergisi
Verified
Journal Article
Open access
PDF file
BOBengi Ozturk
Bengi Ozturk
Atay ve arkadaşlarının “İnflamatuvar bağırsak hastalığı olan hastalarda immünmodülatör tedaviler güvenli mi? 23 yıllık tek merkez deneyimi” çalışmasını ilgiyle okudum. Atay ve arkadaşları bu çalışmada immünmodülatör ajanların yan etkilerini 23 yıllık geriye dönük olarak değerlendirmişler. Bu çalışmada, halihazırda anti-tümör nekrozis faktör (anti-TNF) ajanlar veya anti-integrin ajan ile tedavi edilmekte olup geçmişinde immünmodülatör tedavi almış olan hastalar değerlendirilmiş. Bu çalışmada azatiyopürin kullanım süresini Crohn hastalarında 4.2 ± 3.5 yıl, ülseratif kolit olan hastalarda ise 3.0 ± 2.6 yıl olarak saptamışlar. Ayrıca azatiyopürin kullanmış olan hastaların 18’inde (%5.5), metotreksat kullanmış olan hastaların 6’sında (%7) ilaç kesilmesini gerektirecek yan etkiler geliştiğini ve bu yan etkilerin tamamının 2. derece yan etkilerden oluştuğunu göstermişler ve takip süresince tedavi ilişkili hematolojik veya solid organ malignitesi saptamadıklarını göstermişler (1). Yakın dönemde yapılan çalışmada da immünmodülatör tedavinin güvenli olduğuna dair benzer bulgular gösterilmiştir (2). Azatiyopürin ile monoterapinin 8-9 yıla kadar uzayabildiği ve bu sürelerde dahi güvenli olduğu yönünde bilgiler sunulmaktadır (3,4). Bu çalışmada hastaların tedavi aldıkları süre literatüre kıyasla daha kısadır; sadece monoterapi alıp sonrasında kombine tedaviye ihtiyacı olan hastaları kapsaması nedeniyle, tedavi süresi bu çalışmada daha kısa gibi gözükmektedir. Yan etkilerin daha az görülmesi tedavi süresi kısalığına da bağlı olabilir. Yapılan çalışmalarda, immünmodülatör tedavinin anti-TNF tedavi ile kombinasyonunda etkinliği ve yan etkileri değerlendirilmiş olup; yan etkiler monoterapi grubunda %29.4, kombinasyon grubunda ise %36.3 hastada gösterilmiş (5). Azatiyopürinin anti-TNF tedavi ile kombinasyonunda, azatiyopürinin yan etkileri nedeniyle çalışmanın erken aşamasında çalışmadan ayrılmayla sonuçlandığı gösterilmiştir (6). Bir başka çalışmada ise immünomodülatörlerle kombinasyon tedavisi özellikle immünomodülatör tedaviye biyolojik tedavinin başlamasından 30 günden daha uzun bir süre önce başlandığında, tedaviyi bırakma riskinin önemli ölçüde azaldığı gösterilmiştir (7). Yapılan çalışmalar incelendiğinde anti-TNF ajanla kombine immünmodülatör tedavinin yan etkilerine yönelik birbirinden farklı sonuçların olduğu dikkati çekecektir. Bu çalışmada da, anti-TNF veya anti-integrin ajanlar ile eş zamanlı immünmodülatör tedavi alan hastalar var ise bu hasta grubunun belirtilmesi ve immünmodülatör tedavinin kombine tedavideki yan etki profilinin değerlendirilerek alt grup analizinin ayrıca yapılmasının da literatüre katkı sağlayacağı görüşündeyim.

25 March 2026 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
YPYavuz Emre Parlar
Yavuz Emre Parlar
BOBengi Ozturk
Bengi Ozturk
OKOnur Keskin
Onur Keskin
SISabir İsRafilov
Sabir İsRafilov
TKTaylan Kav
Taylan Kav
EPErkan Parlak
Erkan Parlak
Background/Aims: Primary sclerosing cholangitis (PSC) is a chronic, progressive disease characterized by inflammatory and fibrotic strictures in the intrahepatic and/or extrahepatic bile ducts. Typical cholangiographic findings include multifocal, annular, short bile duct strictures with minimal upstream dilatation. However, in some patients, this dilatation progresses to cystic dimensions. The current study aimed to investigate whether the clinical features and prognosis of patients with cystic dilatation (CD) of the bile ducts differ from those of patients with classic cholangiographic PSC. Materials and Methods: Demographic data, laboratory and clinical findings, and prognostic outcomes of patients with CD of the bile ducts who underwent endoscopic retrograde cholangiopancreatography (ERCP) and/or percutaneous transhepatic biliary drainage at the hospital between 2017 and 2023 were compared with those of patients without CD. Results: Of the 37 patients, 5 (13.5%) had cystic biliary dilatation. Median follow-up was 24 months (range, 12-62) in the CD group and 20 months (range, 8-52) in the non-cystic group. Patients with CD had a higher frequency of cholangitis (median attacks per patient, 1.6 vs. 0.3; P < .001), a greater proportion of recurrent cholangitis (4/5 [80%] vs. 7/32 [21.8%]; P = .038), an increased risk of end-stage liver disease (3/5 [60%] vs. 5/32 [15.6%]; P = .025), and higher mortality (1/5 [20%] vs. 2/32 [6.25%]; P = .045). Median transplant-free survival was significantly shorter in the cystic group (7.1 years [95% CI, 1-9] vs. 19.5 years; P = .017). Conclusion: Cystic dilatation appears to be a clinically relevant prognostic feature in patients with primary sclerosing cholangitis, however, confirmation in larger studies is warranted. Cite this article as: Parlar YE, Öztürk B, Keskin O, et al. Prognostic significance of cystic biliary dilatation in primary sclerosing cholangitis. Turk J Gastroenterol. Published online March 25, 2026. doi:10.5152/tjg.2026.26055.

25 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BOBengi Ozturk
Bengi Ozturk
MÇMUHAMMET FURKAN ÇAKMAK
MUHAMMET FURKAN ÇAKMAK
AOAbdurrahman Ozkan
Abdurrahman Ozkan
ISIbrahim Nahit Sendur
Ibrahim Nahit Sendur
OKOnur Keskin
Onur Keskin
TKTaylan Kav
Taylan Kav
Background/Objectives: Gaucher disease (GD) is a rare lysosomal storage disorder with heterogeneous and often nonspecific clinical manifestations. Despite increasing awareness of Gaucher disease (GD), diagnostic delay remains a clinical challenge because of its heterogeneous and nonspecific presentation. This study evaluated the diagnostic journey of patients with GD, with particular emphasis on diagnostic delay, healthcare specialties encountered before diagnosis, and the involvement of gastroenterology in the diagnostic pathway. Materials and Methods: Patients with GD followed at the Hacettepe University Department of Gastroenterology between January 2014 and December 2024 were included. Demographic and clinical characteristics, age at symptom onset and diagnosis, diagnosis delay, medical specialties consulted before diagnosis, diagnostic methods, GD subtype, and treatment data were obtained from hospital records. Continuous variables were summarized as medians, minimum-maximum values, or interquartile ranges as appropriate, while categorical variables were summarized as frequencies and percentages. Results: Of the 34 patients, 22 (64.7%) were female, and 12 (35.3%) were male. The median age at diagnosis was 17.5 years [minimum(min)–maximum(max), 1–69], and the median age at symptom onset was 9 years (min–max, 1–44). Diagnostic-delay data were available for 21 patients. The median time from symptom onset to diagnosis was 1 year (range, 0–19); 11/21 patients (52.4%) were diagnosed within 1 year, whereas 5/21 (23.8%) experienced a diagnostic delay of ≥5 years. Among patients with available data on the diagnosing specialty, 42.9% were diagnosed in pediatric gastroenterology and 28.6% in adult gastroenterology. Among 23 patients with available prediagnostic referral data, 8 (34.8%) had consulted two or more different medical specialties before diagnosis. Conclusions: Although more than half of the patients with available diagnostic-delay data were diagnosed within 1 year of symptom onset, nearly one-quarter experienced delays of ≥5 years. Gastroenterology services represented a frequent point of diagnosis in this referral-center cohort, although this observation should be interpreted in light of the gastroenterology-based study setting and associated referral and selection bias. These findings should be interpreted cautiously given the small sample size and missing data. Greater awareness of GD in patients presenting with unexplained hepatosplenomegaly and/or cytopenias, together with timely use of disease-specific biochemical and molecular testing, may help shorten the diagnostic journey and reduce unnecessary diagnostic procedures.

21 April 2026 in Akademik Gastroenteroloji Dergisi
Verified
Journal Article
Closed access
YPYavuz Emre Parlar
Yavuz Emre Parlar
MCMehmet Coşkun
Mehmet Coşkun
BOBengi Ozturk
Bengi Ozturk
Backgorund and Aims: Acute pancreatitis ranges from mild disease to severe forms associated with organ failure and mortality. Early risk stratification is essential, yet current scoring systems may not fully reflect early metabolic alterations. While hypocalcemia is a recognized severity marker, the prognostic role of phosphorus remains unclear. This study evaluated whether early phosphorus-to-calcium ratio changes within 48 hours predict disease severity in acute pancreatitis. Materials and Method: This retrospective single-center study included adults hospitalized with acute pancreatitis between January 2023 and December 2025. Phosphorus-to-calcium ratio was calculated from routinely recorded serum phosphorus and calcium levels at admission, 24, and 48 hours. Severity was defined according to the Revised Atlanta Classification. Multivariable logistic regression and receiver operating characteristic analyses were performed. Results: A total of 182 patients were included [mean age 56.8 ± 15.9 years; 100 male (54.9%)]. Mild acute pancreatitis occurred in 140 patients (76.9%), moderately severe in 32 (17.6%), and severe in 10 (5.5%). Persistent organ failure occurred in 12 (6.6%), intensive care unit admission in 14 (7.7%), and in-hospital mortality in 3 patients (1.6%). Phosphorus-to-calcium ratio values increased during the first 48 hours and were higher in moderate-to-severe/severe disease. After adjustment for age, creatinine, C-reactive protein level, and clinical severity score, the 48-hour change in the phosphorus-to-calcium ratio remained independently associated with severity (Odds ratio 1.64, 95% confidence interval 1.14 - 2.36, p = 0.008). Conclusion: Early phosphorus-to-calcium ratio dynamics may serve as a simple adjunct biomarker to existing clinical scores for predicting severity in acute pancreatitis.